Real-World Evaluation of Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease, in an Italian Clinical Setting
, Margherita Andretta 2, Fausto Bartolini 3, Arturo Cavaliere 4, Fulvio Ferrante 5, Alessandro Lupi 6, Romina Pagliaro 7, Rita Pagnotta 8, Stefano Palcic 9, Davide Re 10, Loredana Ubertazzo 11, Adriano Vercellone 12 and Luca Degli Esposti 1
Round 1
Reviewer 1 Report
Perrone et al. present an interesting paper about the real-world evaluation of calcimimetics for the treatment of renal bone disease. This is well-written article and will add to the controversies of this difficult area of treatment.
Author Response
RE: we wish to thank the Reviewer for the positive comment.
Reviewer 2 Report
The figures and charts need to be redrawn to be more readable.
The discussion part is very confused and it should be discussed in depth
It is better to increase the literature review (introduction) with more cited papers
Author Response
The figures and charts need to be redrawn to be more readable.
RE: The figure and chart have been redrawn for more readability.
The discussion part is very confused and it should be discussed in depth
RE: As suggested by the Reviewer, the discussion paragraph has been revised.
It is better to increase the literature review (introduction) with more cited papers
RE: As suggested by the Reviewer, the Introduction paragraph has been revised.
Reviewer 3 Report
Nice representation of pharmaco-utilization of calcimimetics
Add details of the assessment of treatment/medication adherence, Results related to treatment/medication adherence not represented properly given the parameter is discussed in the Discussion and Conclusion Sections.
Author Response
Nice representation of pharmaco-utilization of calcimimetics
RE: we wish to thank the Reviewer for the positive comment.
Add details of the assessment of treatment/medication adherence, Results related to treatment/medication adherence not represented properly given the parameter is discussed in the Discussion and Conclusion Sections.
RE: As suggested by the Reviewer, in the Results paragraph the Figure 2 reporting the pharmaco-utilization data has been added.
